Key Points
- Merit Medical Chairman Fred Lampropoulos sold 25,000 shares on Nov. 21 at an average price of $87.31 for $2,182,750, trimming his stake to 1,029,955 shares (a 2.37% decrease) per an SEC Form 4 filing.
- Company results and outlook remain solid — Merit reported $0.92 EPS vs. $0.82 expected and $384.16M revenue (up 13% YoY), set FY2025 guidance of $3.66–$3.79 EPS, and holds a consensus "Moderate Buy" with an average target of $104.50.
Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) Chairman Fred Lampropoulos sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $87.31, for a total transaction of $2,182,750.00. Following the completion of the sale, the chairman directly owned 1,029,955 shares in the company, valued at $89,925,371.05. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Merit Medical Systems Price Performance
Shares of NASDAQ MMSI opened at $87.17 on Tuesday. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of 44.25, a PEG ratio of 2.62 and a beta of 0.64. The business has a 50-day moving average of $83.89 and a 200-day moving average of $88.43. Merit Medical Systems, Inc. has a 1-year low of $78.12 and a 1-year high of $111.45. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.09 and a quick ratio of 2.66.
Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.92 EPS for the quarter, topping the consensus estimate of $0.82 by $0.10. The business had revenue of $384.16 million for the quarter, compared to analysts' expectations of $371.69 million. Merit Medical Systems had a return on equity of 15.07% and a net margin of 8.31%.The company's revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.86 earnings per share. Merit Medical Systems has set its FY 2025 guidance at 3.660-3.790 EPS. On average, equities analysts anticipate that Merit Medical Systems, Inc. will post 3.37 EPS for the current fiscal year.
Analyst Ratings Changes
MMSI has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $108.00 target price on shares of Merit Medical Systems in a report on Friday, October 31st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Merit Medical Systems in a research report on Monday, November 17th. Barrington Research reiterated an "outperform" rating and issued a $106.00 target price on shares of Merit Medical Systems in a report on Friday, November 14th. Canaccord Genuity Group decreased their price target on Merit Medical Systems from $104.00 to $93.00 and set a "buy" rating for the company in a research note on Friday, November 14th. Finally, Wells Fargo & Company dropped their price objective on Merit Medical Systems from $103.00 to $95.00 and set an "overweight" rating on the stock in a research note on Friday, November 14th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Merit Medical Systems has a consensus rating of "Moderate Buy" and an average target price of $104.50.
Read Our Latest Stock Analysis on Merit Medical Systems
Hedge Funds Weigh In On Merit Medical Systems
A number of large investors have recently bought and sold shares of MMSI. State Street Corp lifted its position in shares of Merit Medical Systems by 1.1% in the second quarter. State Street Corp now owns 2,218,432 shares of the medical instruments supplier's stock valued at $207,379,000 after buying an additional 24,569 shares during the last quarter. Invesco Ltd. raised its position in shares of Merit Medical Systems by 16.4% in the 1st quarter. Invesco Ltd. now owns 1,787,289 shares of the medical instruments supplier's stock valued at $188,934,000 after buying an additional 251,821 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Merit Medical Systems by 8.2% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,766,711 shares of the medical instruments supplier's stock valued at $186,759,000 after purchasing an additional 133,465 shares in the last quarter. Geode Capital Management LLC boosted its position in Merit Medical Systems by 2.8% in the second quarter. Geode Capital Management LLC now owns 1,437,397 shares of the medical instruments supplier's stock valued at $134,384,000 after buying an additional 39,620 shares in the last quarter. Finally, Maverick Capital Ltd. boosted its holdings in shares of Merit Medical Systems by 8.4% during the 2nd quarter. Maverick Capital Ltd. now owns 1,379,408 shares of the medical instruments supplier's stock valued at $128,947,000 after acquiring an additional 106,897 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company's stock.
About Merit Medical Systems
(
Get Free Report)
Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
